Adults 18 to 100, any sex, with Postoperative Nausea. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Upper Extremity)Primary· Baseline (pre-dose) and 30, 60, and 90 minutes post-dose
Neuromonitoring modality utilized during surgical procedures potentially affecting sensory component of central and peripheral nervous system.
SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 4-channel EEG system at baseline (predose) and regularly after study drug administration.
Baseline
Group
Value
95% CI
Fosaprepitant
2.685
± 1.49
30 minutes
Group
Value
95% CI
Fosaprepitant
2.545
± 1.15
60 minutes
Group
Value
95% CI
Fosaprepitant
2.58
± 1.29
90 minutes
Group
Value
95% CI
Fosaprepitant
2.292
± 1.02
Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Upper Extremity)Primary· Baseline (pre-dose) and 30, 60, and 90 minutes post-dose
Neuromonitoring modality utilized during surgical procedures potentially affecting sensory component of central and peripheral nervous system.
SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 4-channel EEG system at baseline (predose) and regularly after study drug administration.
Baseline
Group
Value
95% CI
Fosaprepitant
2.38
± 1.35
30 minutes
Group
Value
95% CI
Fosaprepitant
2.47
± 1.05
60 minutes
Group
Value
95% CI
Fosaprepitant
2.27
± 1.01
90 minutes
Group
Value
95% CI
Fosaprepitant
2.47
± 1.2
Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Lower Extremity)Primary· Baseline (pre-dose) and 30, 60, and 90 minutes post-dose
Neuromonitoring modality utilized during surgical procedures potentially affecting sensory component of central and peripheral nervous system.
SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 4-channel EEG system at baseline (predose) and regularly after study drug administration.
Baseline
Group
Value
95% CI
Fosaprepitant
1.56
± 0.854
30 minutes
Group
Value
95% CI
Fosaprepitant
1.56
± 0.831
60 minutes
Group
Value
95% CI
Fosaprepitant
1.47
± 0.67
90 minutes
Group
Value
95% CI
Fosaprepitant
1.35
± 0.693
Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Lower Extremity)Primary· Baseline (pre-dose) and 30, 60, and 90 minutes post-dose
Neuromonitoring modality utilized during surgical procedures potentially affecting sensory component of central and peripheral nervous system.
SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 4-channel EEG system at baseline (predose) and regularly after study drug administration.
Baseline
Group
Value
95% CI
Fosaprepitant
1.7
± 0.911
30 minutes
Group
Value
95% CI
Fosaprepitant
1.77
± 1.09
60 minutes
Group
Value
95% CI
Fosaprepitant
1.81
± 1.08
90 minutes
Group
Value
95% CI
Fosaprepitant
1.79
± 1.18
Motor Evoked Potentials Amplitude (Left Upper Extremity)Primary· Baseline (pre-dose) and 30, 60, and 90 minutes post-dose
Neuromonitoring modality utilized during surgical procedures affecting motor component of central and peripheral nervous system.
MEPs are generated when stimulation of the brain on the motor cortex (with Transcranial Magnetic Stimulation \[TMS\]) causes the spinal cord and peripheral muscles to produce neuroelectrical signals. MEPs are typically measured in the hand muscles.
Baseline
Group
Value
95% CI
Fosaprepitant
1300
± 1128.48
30 minutes
Group
Value
95% CI
Fosaprepitant
1573.33
± 1508.37
60 minutes
Group
Value
95% CI
Fosaprepitant
1634.89
± 1460.48
90 minutes
Group
Value
95% CI
Fosaprepitant
1544.78
± 1579.12
Sponsor's own description
The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability to accurately measure somatosensory evoked potentials.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 18 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03197064.